Medtech grants in Norway

Closed

Pays 200,000 euros to study bioengineering business ideas that use microgravity.

Closed

Funds small, SME-majority consortia running an early-phase clinical trial to move a biotech therapy, from antibodies to RNA therapies, from the lab towards the market.

Closed

Funds public-private research on the determinants of health, from prevention and early diagnosis to new vaccine strategies and disease-outbreak preparedness.

Closed

Funds public-private research on new health technology assessment methods that value combined, integrated healthcare innovations fairly.

Closed

Funds public-private research that makes integrated healthcare solutions feasible and better matched to what patients and citizens actually need.

Closed

Funds public-private research that connects fragmented health R&I efforts into shared tools, data, platforms and manufacturing processes.

Closed

Funds public-private research on interoperable health data and AI analytics that speed up diagnosis, treatment and personalised care.

Closed

Funds three lead projects, worth up to EUR 15 million each, that each run a multi-stage generative-AI competition in aerospace, pharma or telecom — with EUR 250,000 grants to the top 20 entrants and EUR 2 million grants to the final four.

Closed

Funds research and low-carbon medical technology that cuts the health sector's own emissions while making healthcare systems and communities more resilient to climate change.

Closed

Funds one consortium to build a scannable digital-label standard that replaces cluttered printed labelling on medical devices and diagnostics.

Closed

Funds one coordination project that pilots a digital, data-driven replacement for the paper-heavy conformity assessment process device makers use to get CE marking under the MDR and IVDR.

Closed

Awards EUR 50,000 to one scientist recognised for advancing clinical development of products for poverty-related diseases in Africa.

Closed

Awards EU deep-tech teams up to €2.5 million in lump-sum grants across two stages.

Closed

Funds one consortium to build a certified micro-credentials programme teaching entrepreneurship and innovation to health and life-science students.

Closed

Pays the existing EU Personalised Medicine partnership to bring in new partners and additional activities under an amended grant agreement.

Closed

Funds research teams that use gene and epigenome editing to engineer safer, more effective off-the-shelf cell therapies for one chosen disease area.

Closed

Funds coordination projects that scale up validated digital health and AI tools across national or sub-regional health systems in sub-Saharan Africa.

Closed

Pays one coordination team to run the EU-wide policy forum that gets governments, regulators and industry to agree on which animal-testing-alternative methods are ready for official use.

Closed

Funds one project to build the infrastructure, training and digital tools needed to run same-day orthopaedic and cardiology surgical centres in Europe.

Closed

Supports international consortia so small companies can turn joint innovation into export-ready products.

Closed

Funds the coordination of up to ten existing advanced-therapy research centres into one European network, with a shared roadmap for scaling up gene and cell therapy manufacturing.

Closed

Funds a pan-European network of 10-18 startup and scaleup hubs that can pass on up to EUR 60,000 per deep-tech startup for cross-border scaling support.

Closed

Funds small and medium enterprises across Europe via Eurostars Call 11 for collaborative innovation with international partners.

Closed

Funds the next development stage, TRL 5 and up, for regenerative-medicine results that already came out of an earlier, completed EU-funded research project.